EU project BLUEPRINT releases film on its activities and achievements
What is the link between genes, environment and health? And how can a better understanding of this interaction help us improve the diagnosis, treatment and cure of diseases, such as diabetes and cancer? On the trail of those questions, the European Union launched the large-scale research initiative “BLUEPRINT – A BLUEPRINT of Haematopoietic Epigenomes” (www.blueprint-epigenome.eu) in October 2011. The project set out to further our knowledge of how our genes are activated or repressed, in particular in blood cells of both healthy and diseased individuals. With BLUEPRINT now running in its fifth year, a project film takes stock of the activities and achievements of this outstanding international research endeavour. What could be achieved so far? What drives and motivates the people behind BLUEPRINT? These are only some of the questions addressed by the film, which gives viewers a vivid glance “behind the scenes” and exciting insight into the work of one of Europe’s so-called “High Impact Projects” in medical research. The film is available on the BLUEPRINT website (http://bit.ly/1SDguYY(opens in new window)) About BLUEPRINT Coordinated by Prof. Henk Stunnenberg from Radboud University (Department of Molecular Biology) BLUEPRINT involves an international consortium comprising 39 leading European universities, research institutes and industry entrepreneurs. Funded under the European Union’s Seventh Framework Programme for Research, Technological Development and Demonstration (Grant Agreement No 282510), BLUEPRINT is the European contribution to the International Human Epigenome Consortium (IHEC)(www.ihec-epigenomes.org) an international research cooperation effort in the field of epigenomics gathering research teams and funding agencies around the globe.
Countries
Australia, Belgium, Switzerland, Germany, Denmark, Spain, France, Israel, Italy, Netherlands, Sweden, United Kingdom